Palisade Bio Inc Stock News

Seasoned Pharmaceutical leader bringing over 24 years of experience in clinical development across autoimmune, metabolic, cardiovascular, and gastrointestinal indications

NEW YORK , Oct. 20, 2025 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Palisade Bio, Inc. (NASDAQ: PALI) on behalf of the company's shareholders. The investigation seeks to determine whether Palisade Bio's directors breached their fiduciary duties in connection with recent corporate actions.

First dual-acting anti-inflammatory and anti-fibrotic candidate in development for FSCD, a condition with no approved therapies

PALI-2108 is the first and only PDE4 inhibitor designed to target terminal ileum and colon for fibrostenotic Crohn's disease (FSCD) and ulcerative colitis (UC) to address significant unmet medical needs

Carlsbad, CA, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that the Company determined to cancel its previously adjourned special meeting of stockholders (the “Spec...

Offering was led by B Group Capital and Columbia Threadneedle Investments with significant participation from Adage Capital Partners LP, ADAR1 Capital Management, Boxer Capital Management, Coastlands Capital, Deep Track Capital, Janus Henderson Investors, Octagon Capital, Perceptive Advisors, RA Capital Management, Squadron Capital Management, and a large healthcare dedicated mutual fund

Carlsbad, CA, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc.  (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced the pricing of an underwritten public offering of 171,440,559 shares of its common stock (or co...

Carlsbad, CA, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that the Company's special meeting of stockholders held on September 26, 2025 at 10:00 a.m. Pacific Time...